Orbiflox/Momet/Posaco Eardrops

Verify with FDA CVM →

1,476 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
1,476
Total Reports
44
Deaths Reported
300.0%
Death Rate

Active Ingredients

Orbiflox/Momet/Posaco Eardrops

Administration Routes

Auricular (Otic)UnknownTopicalOralOtherOphthalmicEndotrachealParenteral

Species Affected

Dog 1,312
Unknown 127
Cat 36
Human 1

Most Affected Breeds

Crossbred Canine/dog 291
Unknown 128
Retriever - Labrador 92
Retriever - Golden 56
Terrier - Yorkshire 51
Shih Tzu 46
Chihuahua 45
Pit Bull 43
Terrier - West Highland White 40
Pug 34

Most Reported Reactions

Deafness 767
Partial deafness 190
Drug administration duration too long 175
Lack of efficacy - NOS 77
Underdose 76
Overdose 67
Incorrect dose administered NOS 53
Loss of hearing 52
Product problem 51
Deafness NOS 47
Underfilling, Container 47
Drug dose prescribing error 47

Outcome Breakdown

Recovered with Sequela
733 (54.3%)
Recovered/Normal
237 (17.6%)
Ongoing
200 (14.8%)
Outcome Unknown
135 (10.0%)
Euthanized
24 (1.8%)
Died
20 (1.5%)

Data Summary

Metric Value
Total adverse event reports 1,476
Reports involving death 44
Case-fatality rate (reported events) 300.0%
Distinct species in reports 4
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Orbiflox/Momet/Posaco Eardrops Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 1,476 adverse event reports referencing Orbiflox/Momet/Posaco Eardrops, including 44 reports in which the animal died — a 300.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Orbiflox/Momet/Posaco Eardrops. Reported administration routes include Auricular (Otic), Unknown, Topical, Oral. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Orbiflox/Momet/Posaco Eardrops reports are Dog (1,312 reports), Unknown (127 reports), Cat (36 reports), with Dog accounting for the largest share. Within those species, Crossbred Canine/dog (291), Unknown (128), Retriever - Labrador (92) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Orbiflox/Momet/Posaco Eardrops are Deafness (767), Partial deafness (190), Drug administration duration too long (175), Lack of efficacy - NOS (77). Of the 1,349 reports with a coded outcome, Recovered with Sequela is the leading category at 54.3%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Orbiflox/Momet/Posaco Eardrops.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial